Proactive Investors - Run By Investors For Investors

Breakfast News - TruFin, Life Settlement, IntegraFin and more ....

Breakfast News - TruFin, Life Settlement, IntegraFin and more ....

Small Cap Breakfast

Set menu

AIM:

Total number of AIM Companies (Incl Susp):

955*

Total number of AIM Companies trading:

906*

 *as at close of business  12 February 2018

 

Standard List**  of Main Market:

Total number of Standard List Companies

 (Incl Susp):

136*

Total number of Standard List Companies trading:

122*

*as at close of business  12 February 2018

 

NEX Growth Market:

Total number of NEX Growth Market Companies (Incl Susp):

86*

Total number of NEX Growth Market Companies trading:

82*               

*as at close of business 12February 2018

 

                                *A corporate client of Hybridan LLP

**  Standard Listing as defined by Hybridan LLP to be a business with strictly  operational activity

                                    

Dish of the day

No Joiners Today

 

Off the menu   

No Leavers Today

                                             

What’s cooking in the IPO kitchen?

AIM

Core Industrial REIT—established to invest in Irish-based industrial properties, predominantly located in the Greater Dublin Area . Vendor placing and new funds to a total of €225m, Target gross proceeds €207m.

TruFin—holding company of an operating group comprising three growth-focused FinTech and banking businesses operating in three niche lending markets: supply chain finance, invoice finance and dynamic discounting. Offer raising £70m at 190p with market cap of £185m, expected 21 Feb

Polarean  - The medical drug-device combination companies operating in the high resolution medical imaging market. Offer TBC. Due 22 Feb

Block Energy—a  NEX Listed UK based oil exploration and production company whose main country of operation is the Republic of Georgia, looks to join AIM end of February 2018. Offer TBC

 

Main Market Specialist Funds

Life Settlement—closed-ended investment company whose principal activities will be to support and manage portfolios of whole and partial interests in life settlement policies issued by life insurance companies operating predominantly in the US.  Due 6 Mar.

 

Main Market Premium Listing

IntegraFin provides platform services to UK clients and their financial advisers through its award-winning platform, Transact. Due Mar 18. FYSep2017 PBT up 44% to £29.9m.

GEMS Education—report by Reuters that the private schools group is seeking a $4.5bn to $5bn London float in 2018. FYAug17 rev $926.2m and adjusted EBITDA $261.6m.

CVC (Sky Bet) rumoured to be seeking £2.5bn plus float.

VC firm Augmentum rumoured to be seeking raise up to £125m.

                               

Breakfast buffe

Concepta (LON:CPT) 6.1p £8.43m

“The UK healthcare company and developer of a proprietary product targeted at the mobile health market with a primary focus on women's fertility, is pleased to announce that it has signed a marketing agreement with Wei Yi Bei Lian (Shanghai) Information Technology Co., Ltd ("BB Link").

BB Link offers free WiFi to waiting rooms in 1,500 maternity hospitals across China. Concepta has developed a landing page that will be displayed when patients connect to this WiFi service. The page will give an overview of the myLotus product and a link to the Concepta website where more in depth information can be found. Initially, Concepta's landing page will be launched in a select number of hospitals, and longer term, the Company will be able to reach hundreds of thousands of women in a phased rollout, through a highly targeted marketing channel.” We  could see no forecasts.

 

Stratex International (LON:STI) 0.75p £3.5m

The  gold-focused exploration and development company in Turkey and Africa, is pleased to provide an update on its Hasançelebi and Doğala gold projects in Turkey

Agreement to transfer Hasançelebi and Doğala Exclusive Exploration Licences to TET;

TET to pay Stratex $50k within one week of signing the Agreement;

TET to spend up to $1.5m on exploration and drilling at the Projects within two years

TET to pay Stratex $0.5m success fee (in cash) if minimum JORC-compliant Measured or Indicated resource of 100,000 oz gold (at 0.3 g/t Au cut off) is confirmed within oxide and transition material at Hasançelebi -

Stratex to receive a 1.5% net smelter returns ('NSR') royalty on any future precious metals production at the Licences, and a 5% NSR royalty on the future production of any other metals or industrial raw minerals.

 

Scancell Holdings (LON:SCLP) 12.75p £39.79m

“ISA Pharmaceuticals B.V. ('ISA'), a clinical-stage immunotherapy company, and Scancell Holdings Plc, the developer of novel immunotherapies for the treatment of cancer, are pleased to announce that they have entered into a worldwide licensing and collaboration agreement to use ISA's AMPLIVANT® adjuvant technology for the manufacturing, development and commercialisation of Scancell's first Moditope® developmen­t candidate, Modi-1.  This partnership has the potential to provide a new treatment option for patients with triple negative breast cancer, ovarian cancer, sarcomas, and other solid tumours. Under the terms of this agreement, ISA has granted Scancell an exclusive worldwide license to manufacture, develop and commercialise the AMPLIVANT®:Modi-1 conjugate therapy and will contribute know-how and expertise related to AMPLIVANT®.“ Clinical studies to start H1 2019.

 

Stadium Group (LON:SDM) 119p £45.43m

Recommended cash offer by TT Electronics. 120p per share or £45.8m. 34.7% premium to yesterday’s close.

Stadium is a design-led technology business with a focus on wireless connectivity, power and interface and displays .

FYDec17E rev £61m and PBT £4.5m.

 

LiDCO (LON:LID) 7.37p £18.01m

FYJan18 trading update from the  hemodynamic monitoring company .

“LiDCO product revenues for the year are expected to be up 2% to £6.87m (2017: £6.76m) with total revenues (including third party products) expected to be up by 1% to £8.27m (2017: £8.21m).  Excluding China, where as previously announced no sales were recorded in the year as regulatory approval is sought for a fundamental accessory, LiDCO product revenues were up 9% to £6.87m (2017: £6:27m). During the year the Company launched its latest monitor, LiDCOunity v2, with the new highly differentiated High Usage Programme (HUP) business model. HUP is building momentum after its launch in July 2017, achieving a global installed base of 96 monitors with total annualised revenue of £0.73m. As of 31 January 2018, LiDCO had £0.60m of deferred revenues on the balance sheet arising from the HUP. Overall the new LiDCOunity v2 contributed to the strong demand for monitors with 315 units being sold or placed in the year (2017: 227 units).” FYJan19E rev £11.2m, PBT £1.3m.

 

The People’s Operator (LON:TPOP) 0.1p £3.34m

FYDec17 trading update from the cause-based commercial mobile virtual network operator.

* FY2017 average revenue per user ("ARPU") in the UK of £11.02 (FY2016: £13.22) for PAYG customers and £9.78 (FY2016: £12.50) for PAYM customers

* FY2017 average revenue per user in the US of $20.15 (FY2016: $22.09)

* Average customer acquisition costs remain low at £7.76 in the UK (FY2016: £5.70) and $21.71 (FY2016: $22.00) in the US

* Overall Airtime margin for 2017 is more than five times that of 2016, reflecting ongoing reductions in wholesale rates

* Year-on-year churn has more than halved in the UK and has declined by over 50% in the US

* ARPUs in the UK were affected, particularly in H2 2017, through discounting via affiliate platforms. Such unprofitable discounting has now been discontinued.

 

Earthport (LON:EPO) 12.02p £73.71m

“The leading payment network for cross-border payments, is pleased to provide an unaudited trading update for the six month period ended 31 December 2017 ("H1 FY 2018").

Financial Highlights

* Revenues grew by approximately 8% to £15.4m (H1 FY 2017: £14.3m)

* Adjusted gross margin decreased by 9% to 64% compared to 70% in H1 FY 2017, due to network delivery costs and mix of business

* Administrative expenses increased by approximately 7% to £13.9m (H1 FY 2017: £13m), representing 90% of revenues (H1 FY 2017: 91%)

* Adjusted EBITDA loss increased by approximately £1.7m to £3.2m (H1 FY 2017: £1.5m)

* Cash Balance at 31 December 2017 amounted to £30.6m, compared to £11.9m at 30 June 2017. This includes net proceeds of £24m raised in October 2017”.

 

Innovaderma (LON:IDP) 187.5p £26.96m

HYDec17 results from the UK developer of life sciences, beauty and personal care products.  Group revenue grew strongly by 31% to £4.2m.  Loss before tax of £0.03m (HY2016: £0.15m) due to planned investment in people required to support international growth, and pre-launch product development expenses. Successful launch of the new hair loss treatment and hair care brand, Roots Double Effect  ("Roots") in the UK, both within DTC and Retail channels during Q1 Cash of £2.05m.  Remains confident of meeting market expectations. FYJun18E rev £13.8m and PBT £2.4m.

 

Ten Lifestyle Group (LON:TENG) 160p £125.2m

The “technology-enabled lifestyle and travel platform for the world's wealthy and mass affluent, is pleased to announce it has won a new, additional contract with Visa International ("Visa") to provide concierge services to its high and ultra-high-net-worth clients as part of its Visa Infinite and Visa Signature affluent card concierge programmes. The service will be rolled out in Central Europe, the Middle East and Africa, with the transitioning process having already commenced.” FYAug18E rev £44.7m, PBT loss £10.6m.

 

 

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use